Cargando…
THU266 Lowered HbA1c In Individuals With Long-term Type 1 Diabetes Undergoing BCG Bladder Cancer Therapy
Disclosure: H. Dias: None. W. Kühtreiber: None. D.L. Faustman: None. Originally developed for the prevention of tuberculosis, the bacillus Calmette-Guérin (BCG) vaccine has shown benefit in diverse human diseases, including infection resistance, allergies, multiple sclerosis and autoimmune diabetes....
Autores principales: | Dias, Hans, Kühtreiber, Willem, Faustman, Denise L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553505/ http://dx.doi.org/10.1210/jendso/bvad114.702 |
Ejemplares similares
-
THU284 BCG Clinical Trial Programs In Advanced Type 1 Diabetes - 2023 Update
por: Kühtreiber, Willem M, et al.
Publicado: (2023) -
MON-179 Repeat BCG Vaccination Creates Lasting HbA1c Reductions in Adult Subjects with Longstanding Type 1 Diabetes by Correcting Immune-Metabolic Defects
por: Faustman, Denise, et al.
Publicado: (2019) -
THU322 Lower HbA1c Is Associated With Lower In-Hospital Mortality In Patients With COVID-19
por: Tsikala Vafea, Maria, et al.
Publicado: (2023) -
THU253 The Hemoglobin Wayne Variant And Association With Falsely Elevated HbA1c
por: Mulpuri, Neha, et al.
Publicado: (2023) -
SAT041 (18)F-FDG PET/CT Mapping Of Functional Microbial Niches To Understand Host Glucose Regulation After BCG Vaccinations
por: Dias, Hans, et al.
Publicado: (2023)